Biotron to Present Latest Clinical Trial on HIV-1 Data at CROI

  • Dec 03, 2019 AEDT
  • Team Kalkine

Biotron Limited (ASX: BIT) would be presenting its latest clinical trial data at the Conference on Retroviral and Opportunistic Infections (‘CROI’), to be held in Boston MA, USA in March 2020.

Ever since the company completed the BIT225-009 Phase 2 HIV-1 clinical trial, Biotron has continued to characterise the unique mechanism of action of its lead antiviral drug, BIT225.

BIT225 induces the significant beneficial immunological changes observed in the completed Phase 2 clinical trial and form the basis of the paper to be presented at CROI. The Directors has also announced that the new data from the Phase 2 trial, resulting from these post-trial analyses, have significantly enhanced the company’s intellectual property position.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK